Gain TherapeuticsGANX +1.74%31 FCF Yield % is -25.95 as of Jun. 26, 2026. GuruFocus rates GANX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, Gain Therapeutics ranks worse than 71.37% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Gain Therapeutics FCF Yield % Related Terms
Gain Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Gain Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Gain Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Gain Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Gain Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Gain Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Gain Therapeutics (GANX) has a FCF Yield % of -25.95 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gain Therapeutics and its competitors. According to the industry distribution chart, Gain Therapeutics ranks #1012 out of 1418 companies in the Biotechnology industry, placing it in the top 71.4%.
Is Gain Therapeutics' FCF Yield % too high?
Gain Therapeutics' current FCF Yield % is -25.95. Based on the distribution chart, Gain Therapeutics ranks #1012 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Gain Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Gain Therapeutics' FCF Yield % compare to EXOZ and HYFT?
According to the Biotechnology industry distribution chart, Gain Therapeutics ranks #1012 out of 1418 companies for FCF Yield %. This places Gain Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Gain Therapeutics and its competitors. Gain Therapeutics's current FCF Yield % is -25.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gain Therapeutics stock overvalued right now?
Gain Therapeutics (GANX) has a current FCF Yield % of -25.95. The current FCF Yield % is -25.95. Gain Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Gain Therapeutics (GANX), the current FCF Yield % is -25.95 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.
31GF Score
Get the complete analysis for GANX
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GANX has been successfully added to your 
